TY - JOUR
T1 - Vitamin D Treatment in Primary Hyperparathyroidism
T2 - A Randomized Placebo Controlled Trial
AU - Rolighed, Lars
AU - Rejnmark, Lars
AU - Sikjaer, Tanja
AU - Heickendorff, Lene
AU - Vestergaard, Peter
AU - Mosekilde, Leif
AU - Christiansen, Peer
PY - 2014/1/13
Y1 - 2014/1/13
N2 - Context: Low 25-hydroxy vitamin D (25OHD) levels are common in patients with primary hyperparathyroidism (PHPT) and associated with higher PTH levels and hungry bone syndrome following parathyroidectomy (PTX). However, concerns have been raised on safety of vitamin D supplementation in PHPT. Objective: We aimed to assess safety and effects on calcium homeostasis and bone metabolism of supplementation with high doses of vitamin D in PHPT patients. Design, Setting: This was an investigator-initiated double-blind, randomized, placebo-controlled, parallel-group trial from a single center. Patients: Forty-six PHPT patients were recruited, mean age of 58 (range 29-77) years and 35 (76%) were women. Interventions: Daily supplementation with 70 microgram (2800 IU) cholecalciferol or identical placebo for 52 weeks. Treatment was administered 26 weeks prior to PTX and continued for 26 weeks after PTX. Main Outcome Measures: PTH, calcium homeostasis, and bone metabolism. Results: Preoperatively, 25OHD increased from 50 to 94 nmol/L in the treatment group and decreased from 57 to 52 nmol/L in the placebo group (p
AB - Context: Low 25-hydroxy vitamin D (25OHD) levels are common in patients with primary hyperparathyroidism (PHPT) and associated with higher PTH levels and hungry bone syndrome following parathyroidectomy (PTX). However, concerns have been raised on safety of vitamin D supplementation in PHPT. Objective: We aimed to assess safety and effects on calcium homeostasis and bone metabolism of supplementation with high doses of vitamin D in PHPT patients. Design, Setting: This was an investigator-initiated double-blind, randomized, placebo-controlled, parallel-group trial from a single center. Patients: Forty-six PHPT patients were recruited, mean age of 58 (range 29-77) years and 35 (76%) were women. Interventions: Daily supplementation with 70 microgram (2800 IU) cholecalciferol or identical placebo for 52 weeks. Treatment was administered 26 weeks prior to PTX and continued for 26 weeks after PTX. Main Outcome Measures: PTH, calcium homeostasis, and bone metabolism. Results: Preoperatively, 25OHD increased from 50 to 94 nmol/L in the treatment group and decreased from 57 to 52 nmol/L in the placebo group (p
U2 - 10.1210/jc.2013-3978
DO - 10.1210/jc.2013-3978
M3 - Journal article
SN - 0021-972X
VL - 99
SP - 1072
EP - 1080
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 3
M1 - jc20133978
ER -